SK284059B6 - Spôsob prípravy substituovaných sulfoxidov - Google Patents

Spôsob prípravy substituovaných sulfoxidov Download PDF

Info

Publication number
SK284059B6
SK284059B6 SK48-97A SK4897A SK284059B6 SK 284059 B6 SK284059 B6 SK 284059B6 SK 4897 A SK4897 A SK 4897A SK 284059 B6 SK284059 B6 SK 284059B6
Authority
SK
Slovakia
Prior art keywords
mmol
het
chiral
sulfoxide
titanium
Prior art date
Application number
SK48-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK4897A3 (en
Inventor
Erik Magnus Larsson
Urban Jan Stenhede
Henrik S�RENSEN
Unge Per Oskar Sverker Von
Hanna Kristina Cotton
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284059(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of SK4897A3 publication Critical patent/SK4897A3/sk
Publication of SK284059B6 publication Critical patent/SK284059B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK48-97A 1994-07-15 1995-07-03 Spôsob prípravy substituovaných sulfoxidov SK284059B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider
PCT/SE1995/000818 WO1996002535A1 (fr) 1994-07-15 1995-07-03 Procede de synthese de sulfoxydes substitues

Publications (2)

Publication Number Publication Date
SK4897A3 SK4897A3 (en) 1997-08-06
SK284059B6 true SK284059B6 (sk) 2004-09-08

Family

ID=20394753

Family Applications (1)

Application Number Title Priority Date Filing Date
SK48-97A SK284059B6 (sk) 1994-07-15 1995-07-03 Spôsob prípravy substituovaných sulfoxidov

Country Status (42)

Country Link
US (1) US5948789A (fr)
EP (1) EP0773940B2 (fr)
JP (1) JP3795917B2 (fr)
KR (1) KR100356252B1 (fr)
CN (1) CN1070489C (fr)
AR (1) AR003443A1 (fr)
AT (1) ATE242233T1 (fr)
AU (1) AU688074B2 (fr)
BR (1) BR9508292A (fr)
CA (1) CA2193994C (fr)
CZ (1) CZ297987B6 (fr)
DE (1) DE69530987T3 (fr)
DK (1) DK0773940T4 (fr)
DZ (1) DZ1911A1 (fr)
EE (1) EE03354B1 (fr)
EG (1) EG24534A (fr)
ES (1) ES2199998T5 (fr)
FI (2) FI117672B (fr)
HK (1) HK1008331A1 (fr)
HR (1) HRP950401B1 (fr)
HU (1) HU226361B1 (fr)
IL (1) IL114477A (fr)
IS (1) IS1772B (fr)
MA (1) MA23611A1 (fr)
MX (1) MX9700358A (fr)
MY (1) MY113180A (fr)
NO (1) NO312101B1 (fr)
NZ (1) NZ289959A (fr)
PL (1) PL186342B1 (fr)
PT (1) PT773940E (fr)
RU (1) RU2157806C2 (fr)
SA (1) SA95160294B1 (fr)
SE (1) SE504459C2 (fr)
SI (1) SI0773940T2 (fr)
SK (1) SK284059B6 (fr)
TN (1) TNSN95081A1 (fr)
TR (1) TR199500861A2 (fr)
TW (1) TW372971B (fr)
UA (1) UA47409C2 (fr)
WO (1) WO1996002535A1 (fr)
YU (1) YU49475B (fr)
ZA (1) ZA955724B (fr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
EP1056456A4 (fr) * 1998-01-30 2006-10-25 Sepracor Inc Compositions et procedes d'utilisation du r-lansoprazole
JP2002512263A (ja) * 1998-04-30 2002-04-23 セプラコール， インク． Ｓ−レイブプラゾール組成物及び方法
CA2330139A1 (fr) * 1998-04-30 1999-11-04 Sepracor Inc. Compositions a base de r-rabeprazole et procedes
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60020967T2 (de) 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
WO2001014366A1 (fr) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
AU2001252595A1 (en) * 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Process for producing optically active sulfoxide derivative
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
CA2775616C (fr) * 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Sels de benzimidazoles et leur application
US7285668B2 (en) * 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
AU2002338655A1 (en) * 2001-04-13 2002-10-28 Aspinterm Llc Methods of preparing sulfinamide and sulfoxides
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
CA2474246C (fr) * 2002-03-05 2010-06-29 Astrazeneca Ab Sels d'alkylammonium d'omeprazole et d'esomeprazole
WO2003089408A2 (fr) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Pyridinylmethyl-sulphinyl-benzimidazole substitue optiquement actif et sels
WO2004002982A2 (fr) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
EA200500673A1 (ru) 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
SI1575941T1 (sl) * 2002-12-06 2012-08-31 Nycomed Gmbh Postopek za pripravo (S)-pantoprazola
US7452998B2 (en) * 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
BR0317425A (pt) * 2002-12-16 2005-11-16 Ranbaxy Lab Ltd Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
CA2510849A1 (fr) 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Etats solides de sodium de pantoprazole, leurs procedes de preparation et procedes de preparation d'hydrates de sodium de pantoprazole connus
EP1583507A2 (fr) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Sels de magnesium de derives de l'imidazole
CA2517005A1 (fr) * 2003-02-20 2004-09-02 Santarus, Inc. Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
EP1611901B1 (fr) * 2003-03-13 2013-07-10 Eisai R&D Management Co., Ltd. Medicament destiné à prevenir ou à traiter les grincements de dents
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
EP1608649A2 (fr) * 2003-03-28 2005-12-28 Sidem Pharma SA Procede de preparation enantioselective de derives de sulfoxydes.
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
MXPA05013316A (es) 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
AU2003288703A1 (en) * 2003-12-05 2005-06-24 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005105786A1 (fr) 2004-04-28 2005-11-10 Hetero Drugs Limited Methode servant a preparer des composes de pyridinylmethyl-1h-benzimidazole sous forme d'enantiomeres simples ou enrichis
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
WO2005118569A1 (fr) * 2004-06-02 2005-12-15 Altana Pharma Ag Procede permettant la preparation de composes pyridin-2-yl-methyl-sulfinyl-1h-benzimidazol
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
WO2006001755A1 (fr) * 2004-06-24 2006-01-05 Astrazeneca Ab Nouvelle forme modifiee de cristaux de sels d'esomeprazole sodium
WO2006001753A1 (fr) * 2004-06-24 2006-01-05 Astrazeneca Ab Nouveau procede de preparation de modifications de cristal a utiliser dans la preparation de sel de sodium d'esomeprazole
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
SI1802584T1 (sl) * 2004-10-11 2010-01-29 Ranbaxy Lab Ltd Postopki za pripravo substituiranih sulfoksidov
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
JP4837722B2 (ja) * 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． 置換スルホキシド化合物、その調製方法、およびその使用方法
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
EP1885711A1 (fr) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Sel de strontium d'esomeprazole, procede de preparation de ce sel et compositions pharmaceutiques le contenant
EP1907375B1 (fr) * 2005-06-08 2013-07-24 LEK Pharmaceuticals d.d. Solvate cristallin de sodium d'omeprazole
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
AU2006323245B2 (en) 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US7799925B2 (en) 2005-12-28 2010-09-21 Unión Químico Farmacéutica, S.A. Process for the preparation of the (S)-enantiomer of omeprazole
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
WO2008018091A1 (fr) * 2006-08-08 2008-02-14 Jubilant Organosys Limited Procédé de production de composés de sulfoxyde
EP2065379A4 (fr) 2006-10-13 2011-01-19 Eisai R&D Man Co Ltd Benzimidazole présentant une activité inhibitrice de la sécrétion d'acide gastrique
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
CA2678702A1 (fr) 2007-02-21 2008-08-28 Cipla Limited Procede pour la preparation de esomeprazole magnesium dihydrate
EP2152691B1 (fr) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited Procédé amélioré pour préparer un inhibiteur de la pompe à protons optiquement actif
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) * 2007-10-03 2010-08-19 Ipca Laboratories Ltd. Process for optically active sulfoxide compounds
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
US20110028518A1 (en) * 2008-03-18 2011-02-03 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (fr) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Procédé amélioré de préparation de (s)-oméprazole à partir d'un racémate d'oméprazole à l’aide d'un agent de résolution optique
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
WO2010039885A2 (fr) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Formes cristallines du dexlansoprazole
EP2264024A1 (fr) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Procédé de préparation d'inhibiteurs de la pompe à protons énantiomériquement enrichis
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
EP2438057A4 (fr) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd Procédé d'élaboration de composés sulfoxyde
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
AU2011268774A1 (en) 2010-06-24 2013-01-17 Cipla Limited Salts and polymorphs of dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (fr) 2012-03-22 2013-09-26 Cipla Limited Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929885A1 (fr) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de la pompe à protons
EP2980086B1 (fr) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé efficace pour la préparation d'ésoméprazole (S)-binol complexe
EP3239146A4 (fr) 2014-12-26 2018-05-30 The University of Tokyo Procédé de fabrication d'un composé inhibiteur de la pompe à protons ayant une activité optique
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN113845510A (zh) * 2020-06-27 2021-12-28 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution

Also Published As

Publication number Publication date
ES2199998T5 (es) 2011-03-16
SI0773940T1 (en) 2004-02-29
HU226361B1 (en) 2008-09-29
ES2199998T3 (es) 2004-03-01
ZA955724B (en) 1996-01-15
HUT76642A (en) 1997-10-28
EP0773940A1 (fr) 1997-05-21
KR970704731A (ko) 1997-09-06
FI970102A0 (fi) 1997-01-10
EE03354B1 (et) 2001-02-15
SE9402510L (sv) 1996-01-16
UA47409C2 (uk) 2002-07-15
JPH10504290A (ja) 1998-04-28
NO312101B1 (no) 2002-03-18
CZ297987B6 (cs) 2007-05-16
HRP950401B1 (en) 2004-04-30
DE69530987D1 (de) 2003-07-10
DZ1911A1 (fr) 2002-02-17
NZ289959A (en) 1998-01-26
IL114477A0 (en) 1995-11-27
SE9402510D0 (sv) 1994-07-15
IS1772B (is) 2001-06-01
PL186342B1 (pl) 2003-12-31
WO1996002535A8 (fr) 1999-12-23
CA2193994A1 (fr) 1996-02-01
FI117672B (fi) 2007-01-15
EP0773940B1 (fr) 2003-06-04
TW372971B (en) 1999-11-01
FI970102A (fi) 1997-01-10
YU49475B (sh) 2006-05-25
SA95160294B1 (ar) 2006-07-31
CA2193994C (fr) 2005-05-03
US5948789A (en) 1999-09-07
YU47695A (sh) 1998-07-10
MA23611A1 (fr) 1996-04-01
EP0773940B2 (fr) 2010-11-17
MX9700358A (es) 1997-04-30
SI0773940T2 (sl) 2011-02-28
TR199500861A2 (tr) 1996-06-21
NO970153L (no) 1997-01-14
CZ6497A3 (en) 1997-06-11
DE69530987T3 (de) 2011-07-07
IL114477A (en) 2001-07-24
NO970153D0 (no) 1997-01-14
CN1157614A (zh) 1997-08-20
IS4406A (is) 1996-12-27
TNSN95081A1 (fr) 1996-02-06
PL318165A1 (en) 1997-05-26
DK0773940T4 (da) 2011-02-07
MY113180A (en) 2001-12-31
DK0773940T3 (da) 2003-09-15
RU2157806C2 (ru) 2000-10-20
DE69530987T2 (de) 2004-05-19
EG24534A (en) 2009-08-30
PT773940E (pt) 2003-10-31
AU2994895A (en) 1996-02-16
KR100356252B1 (ko) 2002-11-18
HK1008331A1 (en) 1999-05-07
HRP950401A2 (en) 1997-10-31
BR9508292A (pt) 1997-12-23
SK4897A3 (en) 1997-08-06
FI117830B (fi) 2007-03-15
CN1070489C (zh) 2001-09-05
WO1996002535A1 (fr) 1996-02-01
ATE242233T1 (de) 2003-06-15
AR003443A1 (es) 1998-08-05
AU688074B2 (en) 1998-03-05
SE504459C2 (sv) 1997-02-17
JP3795917B2 (ja) 2006-07-12

Similar Documents

Publication Publication Date Title
SK284059B6 (sk) Spôsob prípravy substituovaných sulfoxidov
CA2226184C (fr) Procede de purification optique pour derives de benzimidazole enrichis par enantiomorphe
US7452998B2 (en) Process for preparing optically pure active compounds
CA2507889C (fr) Procede de preparation de (s)-pantoprazole
MXPA98000160A (en) A process for the optic purification of derivatives of benzimidazol enriquecidos enantiomericame

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20150703